anti-Nipah_005
anti-Nipah_ID | anti-Nipah_005 |
anti-Nipah Drug | Ac-VALDPIDISIVLNKIKSDLEESKEWIRRSNKILDSl-GSGSG-dPEG4-C-(PEG4-Toco)2-NH2 |
Nipah virus strain | NiV (UMMC1 ) |
Approaches used to test anti-Nipah activity | Experimental |
Methods used to test anti-Nipah activity | in-vitro |
Models used to test anti-Nipah activity | 293T |
Mode of infection to test anti-Nipah activity | NA |
Viral titer to test anti-Nipah activity | NA NA |
Mode of Drug delivery for anti-Nipah activity | Culture |
Time of Drug delivery for anti-Nipah activity | NA |
Duration of Drug delivery for anti-Nipah activity | NA |
Drug concentration used to test anti-Nipah activity | NA nM |
Assays used to test anti-Nipah activity | beta-galactosidase complementation assay |
anti-Nipah activity | Decrease [Inhibitory concentration (50 %)] |
References | Mathieu C, Porotto M, Figueira TN, Horvat B, Moscona A Fusion Inhibitory Lipopeptides Engineered for Prophylaxis of Nipah Virus in Primates. J Infect Dis. 2018 Jun 20;218(2):218-227. doi: 10.1093/infdis/jiy152. |
Comments | The experiments provide a proof of concept for the use of antifusion lipopeptides for prophylaxis of lethal NiV |